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Introduction: Elevated blood glucose levels during intensive care unit (ICU) stay, so-called stress hyperglycaemia
(SH), is a common finding. Its relation with a future diabetes risk is unclear. Our objective was to determine the
incidence of disturbed glucose metabolism (DGM) post ICU admission and to identify predictors for future diabetes
risk with a focus on stress hyperglycaemia.
Methods: This single center prospective cohort trial (DIAFIC trial) had a study period between September 2011 and
March 2013, with follow-up until December 2013. The setting was a mixed medical/surgical ICU in a tertiary teaching
hospital in Belgium. 338 patients without known diabetes mellitus were included for analysis. We assessed the level of
glucose metabolism disturbance (as diagnosed with a 75 g oral glucose tolerance test (OGTT) and/or HbA1c level)
eight months after ICU admission, and investigated possible predictors including stress hyperglycaemia.
Results: In total 246 patients (73 %) experienced stress hyperglycaemia during the ICU stay. Eight months post-ICU
admission, 119 (35 %) subjects had a disturbed glucose metabolism, including 24 (7 %) patients who were diagnosed
with diabetes mellitus. A disturbed glucose metabolism tended to be more prevalent in subjects who experienced
stress hyperglycaemia during ICU stay as compared to those without stress hyperglycaemia (38 % vs. 28 %, P = 0.065).
HbA1c on admission correlated with the degree of stress hyperglycaemia. A diabetes risk score (FINDRISC) (11.0 versus
9.5, P = 0.001), the SAPS3 score (median of 42 in both groups, P = 0.003) and daily caloric intake during ICU stay
(197 vs. 222, P = 0.011) were independently associated with a disturbed glucose metabolism.
Conclusions: Stress hyperglycaemia is frequent in non-diabetic patients and predicts a tendency towards
disturbances in glucose metabolism and diabetes mellitus. Clinically relevant predictors of elevated risk included a high
FINDRISC score and a high SAPS3 score. These predictors can provide an efficient, quick and inexpensive way to identify
patients at risk for a disturbed glucose metabolism or diabetes, and could facilitate prevention and early treatment.
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Stress hyperglycaemia (SH) is reported to occur in
50−85 % of critically ill patients admitted to the intensive
care unit (ICU) and is associated with poorer outcome in
a variety of clinical settings (e.g., myocardial infarction,
cardiothoracic surgery, stroke, and trauma) [1–7]. How-
ever, its prevalence is difficult to ascertain due to the
absence in early papers of a universally accepted definition
of SH, inhomogeneity of study populations, differences in
severity of illness, divergent ways of reporting blood glu-
cose readings, and varied timing and frequency of blood
glucose sampling [8]. Contributing factors leading to SH
include inflammatory mediators, excessive release of
counter-regulatory hormones, insulin resistance and med-
ical interventions (e.g., administration of corticosteroids,
vasopressors, dextrose solutions, enteral or parenteral
nutrition, and dialysis). SH is also related to the severity of
the underlying illness or injury [9]. A patient’s predispos-
ition (age, body mass index (BMI), family history of dia-
betes, beta cell reserve) may also play an important role in
the development of SH.
Although strict glycaemic control (80–110 mg/dl) is no
longer advocated for most ICUs, there is a consensus that
manifest hyperglycaemia should be treated and insulin-
induced hypoglycaemia should be avoided [7, 10, 11]. The
Society of Critical Care Medicine has recently published
new guidelines that recommend a target range of
100–150 mg/dl [12].
Few studies, however, provide insight into the long-
term follow up after SH (>140 mg/dl). In one prospect-
ive single-centre study, patients admitted to a medical
ICU were screened post-discharge by an annual 75 g
oral glucose tolerance test (OGTT) during a five-year
follow-up period [13]. 17.1 % of the critically ill patients
with documented SH and normal post-discharge glucose
tolerance developed diabetes mellitus, versus 3.5 % of
subjects who were normoglycaemic during their ICU
stay. Prompt recognition of a disturbed glucose metabol-
ism or diabetes mellitus would lead to optimal thera-
peutic management.
We speculate that SH in patients without prior diagnosis
of diabetes could be a manifestation of a latent disturbance
in the glucose metabolism. Our primary objective was to
determine the incidence of a disturbed glucose metabolism
six to nine months post-ICU admission. We also aimed to
identify predictors of future diabetes risk.
Methods
Setting and participants
This prospective, observational study was performed at
the Antwerp University Hospital, Edegem, Belgium.
During the study period between September 2011 and
March 2013, a total of 3,985 adult critically ill patients
were admitted to the 45-bed mixed medical-surgicalICU (nurse-to-patient ratio 1:2.5 to 1:3.0). Only adult
patients aged between 18 and 85 years admitted for 48 h
or longer to the ICU and who were still alive six months
thereafter were eligible, leaving a total of 1,256 subjects.
Subjects with known diabetes or any other glucose
metabolism disturbance (impaired fasting glucose and/or
impaired glucose tolerance) and individuals using glucose-
lowering drugs were excluded from participation in this
study (n = 262). Other exclusion criteria included esti-
mated short life expectancy, pregnancy and/or a history of
transplantation or acute pancreatic disease. Of the 395
subjects who agreed to participate, 47 did not show up for
the OGTT, leaving 348 subjects, of whom another 10 were
excluded, 4 of whom had existing disturbed glucose
metabolism (treated by oral antidiabetic agents or insulin)
and were missed on first approach. This resulted in 338
subjects being included in the study. These numbers can
be found in Fig. 1.
Glucose control
Blood glucose levels were drawn from an arterial line
and measured using an on-site blood gas analyser
(Rapidlab® 1265, Siemens, München, Germany) and they
were used to adjust the insulin infusion rate. Insulin aspart
(Novo Nordisk, Bagsvaerd, Denmark), in a concentration
of 50 units in 50 cc 0.9 % NaCl, was continuously infused
using the Injectomat Agilia® syringe infusion system
(flow-rate change, range 0.1−200 ml/h, Fresenius Kabi,
Bad Homburg, Germany). During the ICU stay, treatment
of hyperglycaemia was performed using the adapted Yale
protocol, maintaining glycaemia between 60 and 140 mg/dl
[14]. SH was defined as glucose levels exceeding this
threshold of 140 mg/dl, in accordance with the consensus
statement [15]. Patients were fed according to the local
ICU policy, preferably enterally.
Data elements collected
Anthropometric data (length, weight, BMI, waist circum-
ference), preadmission home medication, reason for ICU
admission, parameters of disease severity including the
simplified acute physiology score (SAPS 3), [16, 17] the
daily sequential organ failure assessment score (SOFA
score), [18] and length of stay in hospital and in the ICU,
treatment during ICU stay (steroids, vasopressors, ino-
tropes, mechanical ventilation, insulin), total caloric intake
(based on total parenteral nutrition (TPN), intravenous
(IV) fluids and enteral feeds but without propofol-
associated calories), and laboratory values (C-reactive
protein and lactate levels) were extracted from the elec-
tronic patient records. The following glucose parameters
were analysed in accordance with the consensus report on
glucometrics: maximum and mean glycaemia at day of
admission and at ICU discharge, HbA1c on admission,
mean insulin dose per day, percentage of glucose values in
Fig. 1 Overview of the inclusion process and glucose metabolism status. OGTT oral glucose tolerance test, IFG impaired fasting glucose, IGT impaired
glucose tolerance, DM diabetes mellitus type 2
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stay, and standard deviation of glycaemia in individual
patients) [8].Outcomes and follow up
An outpatient visit was planned approximately six months
after ICU discharge. At the moment of this appointment,
the Finnish diabetes risk score (FINDRISC) questionnaire
(containing age, BMI, waist circumference, diet, exercise,
history of hypertension and personal and family history of
elevated blood glucose) was presented [19]. We also in-
quired about smoking status and home medication, and
length, weight and waist circumference were measured at
that time.A 2-h OGTT with a 75-g glucose load was performed
according to the World Health Organisation (WHO)
guidelines [20, 21]. The following definitions were used
for interpretation of the OGTT result [20]: diabetes
mellitus – fasting plasma glucose ≥126 mg/dl and/or 2-h
plasma glucose during the OGTT ≥200 mg/dl and/or
HbA1c ≥6.5 % (48 mmol/mol); impaired glucose tolerance
– 2-h plasma glucose during the OGTT ≥140 mg/dl but
<200 mg/dl. Impaired fasting glucose was defined as fast-
ing plasma glucose ≥100 mg/dl and <126 mg/dl, according
to the American Diabetes Association guidelines [20].
Statistical analysis
The data are expressed as mean (standard deviation) for
normally distributed continuous variables and as median
Van Ackerbroeck et al. Critical Care  (2015) 19:355 Page 4 of 12(range) for non-normally distributed continuous variables.
Categorical data are expressed as number (percent). The
normal distribution of continuous variables was assessed
with the Kolmogorov-Smirnov method. The unpaired
t test and the Mann–Whitney U test were used to com-
pare means and medians, respectively. For polychotomous
outcome parameters, we used one-way analysis of
variance (ANOVA) with the Bonferroni correction or
Kruskall-Wallis ANOVA with a Tamhane T2 test. A con-
tingency table was generated to assess potential significant
differences between the groups in categorical variables,
and Fisher’s exact test was applied. Based on clinical
judgement and after univariate analysis, we entered all pa-
rameters that could likely be associated with disturbed
glucose metabolism in a logistic regression model, and
assessed the corrected effect of those elements using boot-
strapping. Odds ratios were converted to risk ratios. A
two-tailed P value <0.05 was considered significant.
Statistical analyses were performed with SPSS Statistics
software, version 20.0 for Mac (Armonk, NY, USA).
Ethics
This study was conducted in accordance with the
amended Declaration of Helsinki. The research protocol
was approved by the University of Antwerp and Antwerp
University Hospital Ethics committee (registration
number EC 12/2/22) prior to initiation of the study.
All participants gave signed informed consent.
Results
Population characteristics
The study population consisted of 338 patients (of whom
223 were male); 326 (96 %) were Caucasian. The HbA1c
on admission was measured in 151 patients (45 % of the
total study population) and was <6.5 % in all patients
included for analysis. A total of 246 patients (73 %) had
received insulin therapy during their ICU admission and
were therefore labelled as having experienced SH. The
mean interval between ICU admission and time of OGTT
was eight months, with a 10−90 percentile range of seven
to ten months.
Characteristics comparing the two groups with normal
and disturbed glucose metabolism
A total of 119 patients (35 %) had an abnormal OGTT
result; 27 patients (8 %) had impaired fasting glucose
only, 43 (13 %) had impaired glucose tolerance only, and
25 (7 %) had both impaired fasting glucose and impaired
glucose tolerance; in 24 (7 %) the criteria for diabetes
mellitus were met (Fig. 1). Among the 24 patients diag-
nosed with diabetes, only 5 had an HbA1c ≥6.5 % at the
time of the OGTT, indicating that the diagnosis was
made in the early stages of the disease for most diabetes
patients. On the other hand, 1 out of 24 patientsdiagnosed with diabetes on the basis of an HbA1c
≥6.5 % had an OGTT not indicating diabetes, and would
have been misclassified when only performing an
OGTT. Patients who had experienced SH during their
ICU stay tended to be more frequently affected by dis-
turbed glucose metabolism (38 % vs. 28 %, P = 0.065)
and diabetes (9 % vs. 4 %, P = 0.246) than the normogly-
caemic group (Fig. 2).
Table 1 compares baseline characteristics, disease sever-
ity parameters, metabolic parameters and FINDRISC
score in subjects with normal glucose metabolism and
those with disturbed glucose metabolism. Subjects admit-
ted to the ICU after surgery tended to be more prone to
develop disturbed glucose metabolism than medical ICU
patients (P = 0.051). Most parameters of disease severity
(SAPS 3 and SOFA score, mechanical ventilation and
length of stay at the hospital and in the ICU) were com-
parable between the two groups. Those with disturbed
glucose metabolism were not more severely ill at the time
of their ICU stay than those with normal glucose toler-
ance. Vasopressor and inotropic therapy, but not cortico-
steroid treatment was more frequently administered in the
group that later developed disturbed glucose metabolism.
Important differences in metabolic parameters were
observed between the two groups during their stay at
the ICU. Patients with disturbed glucose metabolism
had a higher HbA1c on ICU admission (P = 0.025) and
required a higher mean insulin dose per day (P = 0.048).
Additionally, fewer patients received TPN in this group
(1 vs. 15 subjects, P = 0.013) and the caloric intake was
statistically significantly lower (P = 0.013). However, the
percentage of glucose values within target, mean gly-
caemia and standard deviation of glycaemia in individual
patients did not differ significantly between the normal
and the disturbed glucose metabolism (DGM) group.
Several metabolic parameters on the last day of ICU
stay (ICU exit parameters) were higher in patients with
disturbed glucose metabolism (CRP, lactate, mean and
maximum glucose), indicating that these patients had
more severe metabolic disturbances upon discharge.
The FINDRISC score was significantly higher in the
group with disturbed glucose metabolism, with 28.2 % of
patients having a FINDRISC score ≥14, compared to
14.3 % in the group of patients with normal glucose
metabolism (P = 0.003). As expected, the same was true
for the HbA1c measured during the OGTT (P <0.001).
Independent predictors for disturbed glucose metabolism
after ICU stay
We further investigated the possible predictors of disturbed
glucose metabolism through multivariate analysis, incorp-
orating clinically important parameters that were signifi-
cantly correlated in univariate analysis: FINDRISC score,
HbA1c on admission, calories per day and relevant
Fig. 2 Glucose metabolism status of patients with and without stress hyperglycaemia during ICU admission. OGTT oral glucose tolerance test,
IFG impaired fasting glucose, IGT impaired glucose tolerance, DM diabetes mellitus type 2
Van Ackerbroeck et al. Critical Care  (2015) 19:355 Page 5 of 12laboratory values on the last day (CRP, lactate). The baseline
anthropometric characteristics are already integrated in the
FINDRISC score. The SAPS III score, the presence of SH
and the use of steroid drugs during ICU stay were included
as well, likely being clinically relevant but not significantly
associated in the univariate analysis. The FINDRISC score
(P = 0.001), the SAPS III score (P = 0.003) and the mean
caloric intake per day (P = 0.011) were associated with
disturbed glucose metabolism in this multivariate analysis.
Patients with a FINDRISC score ≥14 had more than a 50 %
chance of developing disturbed glucose metabolism. When
excluding the FINDRISC score from the multivariate ana-
lysis, the presence of SH was predictive of future disturbed
glucose metabolism as well (relative risk (RR) = 2.221, 95 %
CI 1.201, 2.995, P = 0.033). The median caloric intake per
day was marginally lower (197 vs. 222 kcal/day, P = 0.021)
in the group with disturbed glucose metabolism.
The value of the HbA1c concentration on admission
A higher HbA1c level on admission, even when still
within the normal range, was associated with a higher
insulin need during the ICU stay (r = 0.308, P <0.001,
Fig. 3a), and with a higher risk of disturbed glucose
metabolism afterwards, albeit only in univariate analysis.
In addition, subjects with a higher HbA1c at the time
of ICU admission also displayed a higher HbA1c eight
months later (r = 0.552, P <0.001, Fig. 3b).
Characteristics comparing the two groups with and
without stress hyperglycaemia
Table 2 compares patients with and without SH during
ICU admission. SH was more prevalent in surgical pa-
tients as compared to medical ICU patients. SH wasmost commonly found in patients admitted for cardio-
vascular reasons. Patients with SH were more severely ill
as demonstrated by a higher SOFA score, more vaso-
pressor and/or inotropy need, more need for mechanical
ventilation, and a longer stay in ICU. The FINDRISC
score was also higher in subjects with SH.
Discussion
This prospective analysis is one of the largest and most
detailed to date to study the relationship between SH
and post ICU glucose tolerance in a mixed ICU popula-
tion without known diabetes. SH is frequent in non-
diabetic ICU patients, but whether this is a manifestation
of a latent disturbance in the glucose metabolism, and
puts an individual at a higher risk of future diabetes
remains unclear [13, 22–24]. Glucose metabolism was dis-
turbed in 35 % of patients post ICU admission, of whom
7 % were diagnosed with diabetes. We are, to the best of
our knowledge, the first to explore this in a mixed ICU
population (medical and surgical patients) and to identify
the SAPS III score as a predictor of disturbed glucose me-
tabolism after an ICU stay. We also observed that a higher
FINDRISC score is a valid tool to screen for subjects at
high risk of developing disturbed glucose metabolism or
diabetes in this population.
Incidence of disturbed glucose metabolism in comparison
with previous data
Only one other study prospectively screened patients
previously admitted to an ICU [13]. Performing an
annual 75-g OGTT during a five-year follow-up period,
the authors observed that 17.1 % of the critically ill
patients with documented SH and normal post-discharge
Table 1 Parameters of patients with normal and disturbed glucose metabolism
Normal DGM P value
Group size (n = 219) (n = 119)
Baseline characteristics
Sex
Men 131 (59.8 %) 92 (77.3 %) 0.001
Women 88 (40.2 %) 27 (22.7 %)
Age, years 57 (18–88) 67 (29–83) <0.001
Weight, kg 75 ± 14 80 ± 16 0.003
Body mass index, kg/m2 25 (16–41) 26 (18–41) 0.002
Waist, cm 93 (66–124) 99 (66–133) <0.001
Reason for admission
Medical 84 (38.4 %) 33 (27.7 %)
NS
Surgical 135 (61.6 %) 86 (72.3 %)
Primarily involved organ system
Cardiovascular 108 (49.3 %) 71 (59.7 %) NS
Respiratory 46 (21.0 %) 20 (16.8 %) NS
Digestive 16 (7.3 %) 6 (5.0 %) NS
Renal 4 (1.8 %) 3 (2.5 % NS
Hepatic 8 (3.7 %) 3 (2.5 %) NS
Haematologic 2 (0.9 %) 0 (0.0 %) NS
Neurologic 53 (24.2 %) 19 (16.0 %) NS
Disease severity
Simplified acute physiology score III 42 (16–90) 42 (23–85) NS
SOFA score on admission 8 (1–18) 8 (2–19) NS
Maximum SOFA score during admission 8 (2–20) 8 (2–19) NS
Vasopressor/inotropic therapy 120 (54.8 %) 79 (66.4 %) 0.039
Corticosteroid therapy 35 (16.0 %) 12 (10.1 %) NS
Mechanical ventilation 134 (61.2 %) 73 (61.3 %) NS
Length of stay at the ICU, hours 95 (39–1416) 94 (37–503) NS
Length of stay at the hospital, days 15 (3–163) 14 (2–86) NS
Metabolic parameters
Mean glycaemia, day 1, mg/dl 130 (83–469) 130 (86–232) NS
SD glycaemia, day 1 22 (1–615) 22 (4–168) NS
Maximum glycaemia, day 1, mg/dl 168 (87–591) 166 (86–600) NS
Number of patients with hypoglycaemic
event, day 1
11 (5.1 %) 7 (5.9 %) NS
glucose values in target, 60–140 mg/dl
(%, range)
70 (0–100) 67 (14–100) NS
Mean (SD) glycaemia, mg/dl 128 (18) 131 (27) NS
Median (IQR) glycaemia, mg/dl 129 (120–137) 130 (117–140) NS
SD glycaemia levels in individual patients, mg/dl,
median (range)
27 (19–34) 30 (21–40) NS
HbA1c on admission, (%) 5.5 (4.7–6.2) 5.6 (5.0–6.4) 0.025
HbA1c on admission, (mmol/mol) 37 (28–44) 38 (31–46)
Insulin therapy 153 (69.9 %) 93 (78.2 %) NS
Mean insulin dose, units/day 9 (0–100) 12 (0–99) 0.048
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Table 1 Parameters of patients with normal and disturbed glucose metabolism (Continued)
Total parental nutrition 15 (6.8 %) 1 (0.8 %) 0.013
Caloric intake, kcal/day 222 (0–2127) 197 (32–1911) 0.013
ICU exit parameters
C-reactive protein, last day, mg/l 5.7 (0.0-30.0) 8.1 (0.0-29.0) 0.015
Lactate, last day, mmol/l 1.3 (0.4-79.0) 1.5 (0.7-4.0) 0.006
Mean glucose last day, mg/dl 115 (84–164) 122 (82–217) <0.001
Maximum glucose, last day, mg/dl 136 (91–438) 157 (94–636) 0.001
FINDRISC score 9.5 (0–20) 11 (3–21) <0.001
FINDRISC score ≥14 30 (14.3 %) 33 (28.2 %) 0.003
HbA1c upon OGTT, (%) 5.4 (4.3-6.1) 5.6 (4.9-8.4) <0.001
HbA1c upon OGTT, (mmol/mol) 36 (23–43) 38 (30–68)
HbA1c ≥6.5 % upon OGTT 0 5 (4.2 %) 0.005
Numbers are mean ± SD for continuous, normally distributed data, median (range) for continuous, not normally distributed data, and absolute and relative numbers for
discontinuous data. Day 1 = first 24 h of admission. Hypoglycaemic event = 1 glucose value <60 mg/dl. P value was deemed significant when <0.05. DGM disturbed
glucose metabolism, NS non-significant, SOFA sequential organ failure assessment, FINDRISC Finnish diabetes risk score, HbA1c glycated haemoglobin, OGTT oral glucose
tolerance test
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jects who were normoglycaemic during their ICU stay.
However, a direct comparison with our study is difficult.
The subjects in this study had a considerably longer
follow-up period (five years). Although it provides an in-
teresting long-term perspective, this automatically results
in greater age and therefore higher incidence of disturbed
glucose metabolism. In addition, the authors did not
measure the HbA1c levels on admission and may have
under-diagnosed diabetes at the time of ICU admission.
Another consideration is the fact that we, unlike Gornik
et al., followed a strict insulin treatment protocol in our
ICU, thereby avoiding severe derailing of the glucose
metabolism.
McAllister et al. performed a retrospective study in a
large Scottish cohort, demonstrating that plasma glucose
measured during emergency hospital admission pre-
dicted subsequent risk of developing diabetes type 2
[25]. The three-year risk was <1 % when admission
glycaemia was ≤90 mg/dl, increasing to 2.6 % at
126 mg/dl, to 9.9 % at 200 mg/dl, and to approxi-
mately 15 % at 270 mg/dl. However, the only gluco-
metric data reported in that study were for admission
glucose, and the authors could not state whether
these glucose values were taken in fasting or non-
fasting conditions. We performed a broader analysis
of glucometric data but did not observe significant
differences between the normal and disturbed glucose
metabolism group in the percentage of glucose values
within target, mean glycaemia or SD of glycaemia in
individual patients during their ICU stay. In contrast,
glucose values on the last day of the ICU stay were
significantly higher in those subjects developing dis-
turbed glucose metabolism.Identifying predicting factors for disturbed glucose
metabolism
Diabetes mellitus is a growing health problem worldwide
and is reaching epidemic proportions [26]. Given the
major implications following the diagnosis of disturbed
glucose metabolism or diabetes and the potential bene-
fits of an early adjustment of lifestyle and treatment, it is
important to identify people who are at risk of develop-
ing diabetes.
In this study, the FINDRISC score and SAPS III on
admission were positively correlated with disturbed glu-
cose metabolism and mean caloric intake during the
ICU stay was negatively correlated with disturbed glu-
cose metabolism. Disturbed glucose metabolism also
tended to be more prevalent in patients who experi-
enced SH during the ICU stay as compared to those
without SH. Patients with SH were more severely ill as
demonstrated by a higher SOFA score, more vasopressor
and/or inotropy need, more need for mechanical ventila-
tion, and a longer stay in the ICU. The difference in
length of stay can be considered as a confounder taking
the more frequent blood glucose measurements into
account, which are performed when patients stay longer
in the ICU. However, the degree of SH, reflected by the
mean insulin dose per day was significantly correlated
with the OGTT result. In the study by Gornik et al.,
patients with a positive family history of diabetes and with
a higher BMI were also more prone to develop diabetes
[13]. Both factors are included in the FINDRISC score.
The FINDRISC score was higher in those with SH
during ICU admission. We suspect that SH might be a
manifestation of a latent disturbance in the glucose me-
tabolism. Of all investigated parameters, background
clinical characteristics of patients (such as those
Fig. 3 a Correlation between glycated haemoglobin (HbA1c) on admission and need for insulin during ICU admission. b Relation between HbA1c
on admission and upon oral glucose tolerance test (OGTT) after 8 months. HbA1c is expressed as percent. Three parallel lines represent the mean
and 95 % CI; the fourth and steepest line is a line connecting equal values on the x and y axis. The values that are located under this fourth line
have decreased (improved), while those above the line have increased (deteriorated)
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associated with the future development of DM or dis-
turbed glucose metabolism. Patients with a higher FIN-
DRISC score thus seem to be more likely to have
disturbed glucose tolerance after and during their ICU
stay, as reflected by the development of SH. Our results
show a 10 % increased risk of SH with a one-point
increase in the FINDRISC score. The underlyingphysiological rationale is most likely to be insulin resist-
ance, as several components of the FINDRISC score, such
as age, BMI, waist circumference, lack of exercise, history
of hypertension and personal and family history of ele-
vated blood glucose are associated with insulin resistance.
The HbA1c concentration on admission correlated with
a disturbed glucose metabolism after hospital discharge.
Other studies in non-ICU settings such as acute stroke
Table 2 Parameters of patients with and without stress hyperglycaemia
Normal SH P value
Group size (n = 92) (n = 246)
Baseline characteristics
Sex
Men 53 (57.6 %) 170 (69.1 %) 0.053/NS
Women 39 (42.4 %) 76 (30.9 %)
Age, years 56 (18–82) 62 (20–88) 0.005
Weight, kg 74 ± 15 78 ± 15 0.027
Body mass index, kg/m2 25 (16–41) 26 (17–41) 0.006
Waist, cm 93 (66–128) 96 (66–133) 0.030
Reason for admission
Medical 52 (56.5.4 %) 65 (26.4 %) <0.001
Surgical 40 (43.5 %) 181 (73.6 %)
Primarily involved organ system
Cardiovascular 30 (32.6 %) 149 (60.6 %) <0.001
Respiratory 22 (23.9 %) 44 (27.9 %) NS
Digestive 7 (7.6 %) 15 (6.1 %) NS
Renal 0 (0.0 %) 7 (2.8 %) NS
Hepatic 5 (5.4 %) 6 (2.4 %) NS
Haematologic 1 (1.1 %) 1 (0.4 %) NS
Neurologic 32 (34.8 %) 40 (16.3 %) 0.001
Disease severity
Simplified acute physiology score III 41 (16–76) 42 (18–90) NS
SOFA score on admission 5 (2–16) 8 (1–19) <0.001
Maximum SOFA score during admission 6 (2–16) 8 (2–20) <0.001
Vasopressor/inotropic therapy 18 (19.6 %) 181 (73.6 %) <0.001
Corticosteroid therapy 11 (12.0 %) 36 (14.6 %) NS
Mechanical ventilation 20 (21.7 %) 187 (76.0 %) <0.001
Length of stay in the ICU, hours 82 (39–1075) 99 (37–503) <0.001
Length of stay in hospital, days 14 (2–163) 3 (3–115) NS
Metabolic parameters
Mean glycaemia, day 1, mg/dl 121 (87–217) 134 (86–232) <0.001
SD glycaemia, day 1 13 (1–99) 26 (5–168) <0.001
Maximum glycaemia, day 1, mg/dl 137 (87–348) 176 (91–600) <0.001
Number of patients with hypoglycaemic
event, day 1
1 (1.1 %) 17 (6.9 %) NS
HbA1c on admission, (%) 5.4 (4.7–5.9) 5.5 (4.9–6.6) 0.004
HbA1c on admission, mmol/mol 36 (28–41) 37 (30–49)
Total parental nutrition 15 (6.8 %) 1 (0.8 %) 0.013
Caloric intake, kcal/day 214 (29–2048) 206 (0–2127) NS
ICU exit parameters
C-reactive protein, last day, mg/l 5.4 (0.0-30.0) 7.1 (0.0-29.0) 0.025
Lactate, last day, mmol/l 1.0 (0.4-79.0) 1.5 (0.4-21.2) <0.001
Mean glucose last day, mg/dl 111 (87–217) 119 (82–209) <0.001
Maximum glucose, last day, mg/dl 127 (94–296) 148 (91–636) <0.001
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Table 2 Parameters of patients with and without stress hyperglycaemia (Continued)
FINDRISC score 9.0 (0–21) 10.0 (0–21) 0.001
FINDRISC score ≥14 11 (12.6 %) 52 (21.7 %) NS
HbA1c upon OGTT (%) (mmol/mol) 5.4 (4.3-8.4) 5.5 (4.8-6.7) 0.001
HbA1c upon OGTT, mmol/mol 35 (24–68) 37 (29–50)
HbA1c ≥6.5 % upon OGTT 2 (2.2 %) 3 (1.2 %) NS
Numbers are mean ± SD for continuous, normally distributed data, median (range) for continuous, not normally distributed data, and absolute and relative numbers for
discontinuous data. Day 1 = first 24 h of admission. Hypoglycaemic event = 1 glucose value <60 mg/dl. P value was deemed significant when <0.05. DGM disturbed
glucose metabolism, NS non-significant, SOFA sequential organ failure assessment, FINDRISC Finnish diabetes risk score, HbA1c glycated haemoglobin
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[24, 27–29]. Furthermore, we observed an association
between the HbA1c concentration on admission and the
degree of SH being reflected by the mean insulin dose per
day. Considering all patients had an HbA1c <6.5 % on ad-
mission, we can argue that even when within the normal
range, elevated HbA1c indicates a predisposition to SH,
demonstrating a pre-existing tendency towards glucose
metabolism disturbances including diabetes. These
findings are in agreement with those of other studies,
which concluded that above a certain threshold of
disease severity the degree of SH is no longer solely
determined by the severity of illness itself; instead, it
can be determined by the underlying reserve of the
glucose metabolism [24, 30]. The HbA1c on
admission reflects this reserve. These findings support
our hypothesis that SH is an expression of latent
xdisturbance of glucose metabolism rather than a
causative mechanism. The fact that the disease sever-
ity characteristics and interventions during the ICU
stay (including corticosteroid treatment) did not cor-
relate with the OGTT result in the univariate analysis
further supports this hypothesis.
The median caloric intake was only approximately
200 kcal per day, with only 25 kcal per day difference
between those with normal and disturbed glucose metab-
olism. It is unlikely that this relatively small difference is
of clinical relevance. Caloric intake was low because 65 %
of the study population consisted of surgical patients and
the policy of nil per os on the first day after surgery.
Limitations
In our study we only included adult patients admitted
for ≥48 h to the ICU. Based on the exclusion criteria,
the number of patients who were eligible to participate
was relatively small, making it difficult to generalize the
results. However, determining the true prevalence of
diabetes mellitus and disturbed glucose metabolism in
critically ill patients is difficult. To exclude patients with
a history of disturbed glucose metabolism, we used the
medical file records and the HbA1c on admission. Al-
though HbA1c values are considered superior to the
OGTT and fasting plasma glucose as a diagnostic toolduring hospital admission, not all diabetes patients have
an HbA1c ≥6.5 % in the early stages of the disease
[20, 31]. However, a large proportion of patients might still
bear the effects of SH when an OGTT is performed too
soon after admission, which might lead to false positive
results and over-diagnosis.
The FINDRISC score was an efficient predictor of
OGTT abnormalities. This score was calculated upon the
execution of the OGTT, i.e., approximately eight months
after ICU admission. A number of patients may have
implemented lifestyle changes after they were admitted to
the ICU. Therefore, theoretically there could be a differ-
ence if the FINDRISC score is calculated before hospital
discharge.
Due to the nature of our study in which patients
actively had to visit the hospital for the OGTT, those
patients who remained severely ill or were less mobile
(and therefore might run a higher risk of disturbed glu-
cose metabolism or diabetes) may not have been able to
participate in the study. This probably induces a negative
bias, underestimating the prevalence of disturbed glu-
cose metabolism.
Conclusions
We observed disturbed glucose metabolism in one out of
three patients approximately eight months after ICU ad-
mission. SH during the ICU stay might be an expression of
latent impairment of glucose metabolism, which is demon-
strated by the tendency towards disturbed glucose metabol-
ism and diabetes mellitus after discharge. However, the fact
that not only those who experienced SH, but also those
who remained normoglycaemic during their ICU stay
developed disturbed glucose metabolism, emphasizes the
fact that SH is not the only factor that predicts subsequent
development of disturbed glucose metabolism. Clinically
relevant factors associated with disturbed glucose metabol-
ism in this study are a high FINDRISC score and a higher
SAPS III on admission. These predictors can provide an
efficient, quick and inexpensive way to identify patients at
risk of disturbed glucose metabolism or diabetes. System-
atic screening and prompt recognition of disturbed glu-
cose metabolism or diabetes may lead to optimised
therapeutic management.
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 HbA1c on ICU admission correlates with the degree
of ICU-related stress hyperglycaemia
 Eight months post ICU admission (for ≥36 h), 35 %
of subjects have disturbed glucose metabolism
 Eight months post ICU admission (for ≥ 36 h), 7 %
of patients are diagnosed with diabetes mellitus
 Disturbed glucose metabolism post ICU admission
tended to be more prevalent in patients who
experienced stress hyperglycaemia during their
ICU stay
 A validated diabetes risk questionnaire (FINDRISC)
and SAPS III provide an efficient way to identify
patients at risk of disturbed glucose metabolism
after ICU discharge
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